Nearly one in 20 people who had a SARS-CoV-2 infection go on to experience myalgic encephalomyelitis/chronic fatigue syndrome ...

Shionogi’s S-892216 is being developed as a pre-exposure prophylaxis (PrEP) drug for Covid-19. Credit: seksan Mongkhonkhamsao ...

Jake Sullivan, the outgoing national security adviser, is asking a panel of outside experts to examine the government’s ...

The risk for myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is increased following COVID-19, according to study findings.

Researchers report the ability of tofacitinib to reduce infection risk with SARS-CoV-2 in individuals who are deficient in ...

Jay Bhattacharya Will Bring Transparency to NIH . Dr. Andrew Noymer is an epidemiologist and population health scientist who ...

Semliki Forest virus was originally isolated from mosquitoes in the Semliki Forest, Uganda, hence the name. Upon systemic infection from mosquito bites, Semliki Forest virus causes mild blood viremia ...

Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereafter “Shionogi”) ...

In early December, health officials in the Democratic Republic of the Congo, or DRC, announced that an unknown illness had ...

It started as a respiratory illness - or so everyone thought. But it quickly became apparent that SARS-CoV-2, the virus that ...

Vaccination prior to COVID-19 infection does not significantly affect neurologic symptoms in patients with long COVID.

H.C. Wainwright analyst Edward White reiterated a Buy rating on InflaRx (IFRX – Research Report) today and set a price target of $8.00.Stay ...